Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. more
Time Frame | CGEM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.09% | -3.72% | -0.05% |
1-Month Return | -12.27% | -1.85% | 2.75% |
3-Month Return | -30.3% | -11.4% | 7.4% |
6-Month Return | -37.96% | -4.41% | 10.47% |
1-Year Return | 29.24% | 4.13% | 27.57% |
3-Year Return | -23.18% | 0.3% | 29.56% |
5-Year Return | -60.55% | 36.62% | 89.3% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 18.94M | 18.94M | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 70.00K | 62.00K | 53.00K | 93.00K | 310.00K | [{"date":"2019-12-31","value":22.58,"profit":true},{"date":"2020-12-31","value":20,"profit":true},{"date":"2021-12-31","value":17.1,"profit":true},{"date":"2022-12-31","value":30,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (70.00K) | (62.00K) | 18.94M | (93.00K) | (310.00K) | [{"date":"2019-12-31","value":-0.37,"profit":false},{"date":"2020-12-31","value":-0.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.49,"profit":false},{"date":"2023-12-31","value":-1.64,"profit":false}] |
Gross Margin | - | (0.33%) | 100.00% | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 22.27M | 60.34M | 86.90M | 132.14M | 191.09M | [{"date":"2019-12-31","value":11.65,"profit":true},{"date":"2020-12-31","value":31.57,"profit":true},{"date":"2021-12-31","value":45.47,"profit":true},{"date":"2022-12-31","value":69.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (22.27M) | (60.34M) | (67.95M) | 144.65M | (191.09M) | [{"date":"2019-12-31","value":-15.4,"profit":false},{"date":"2020-12-31","value":-41.71,"profit":false},{"date":"2021-12-31","value":-46.98,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-132.11,"profit":false}] |
Total Non-Operating Income/Expense | 1.24M | 1.76M | 946.00K | 13.28M | 43.49M | [{"date":"2019-12-31","value":2.84,"profit":true},{"date":"2020-12-31","value":4.06,"profit":true},{"date":"2021-12-31","value":2.18,"profit":true},{"date":"2022-12-31","value":30.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (21.65M) | (59.46M) | (67.48M) | 151.32M | (169.22M) | [{"date":"2019-12-31","value":-14.31,"profit":false},{"date":"2020-12-31","value":-39.29,"profit":false},{"date":"2021-12-31","value":-44.6,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-111.83,"profit":false}] |
Income Taxes | (1.62M) | (8.61M) | (2.44M) | 42.12M | (14.12M) | [{"date":"2019-12-31","value":-3.84,"profit":false},{"date":"2020-12-31","value":-20.44,"profit":false},{"date":"2021-12-31","value":-5.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-33.53,"profit":false}] |
Income After Taxes | (20.04M) | (50.85M) | (65.04M) | 109.19M | (155.10M) | [{"date":"2019-12-31","value":-18.35,"profit":false},{"date":"2020-12-31","value":-46.57,"profit":false},{"date":"2021-12-31","value":-59.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-142.04,"profit":false}] |
Income From Continuous Operations | (21.65M) | (59.46M) | (65.57M) | 109.19M | (155.10M) | [{"date":"2019-12-31","value":-19.83,"profit":false},{"date":"2020-12-31","value":-54.45,"profit":false},{"date":"2021-12-31","value":-60.05,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-142.04,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.04M) | (50.85M) | (65.04M) | 111.21M | (153.16M) | [{"date":"2019-12-31","value":-18.02,"profit":false},{"date":"2020-12-31","value":-45.72,"profit":false},{"date":"2021-12-31","value":-58.48,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-137.72,"profit":false}] |
EPS (Diluted) | (2.60) | (4.79) | (1.50) | 2.37 | (3.69) | [{"date":"2019-12-31","value":-109.86,"profit":false},{"date":"2020-12-31","value":-202.05,"profit":false},{"date":"2021-12-31","value":-63.36,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-155.7,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CGEM | |
---|---|
Cash Ratio | 23.88 |
Current Ratio | 24.46 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CGEM | |
---|---|
ROA (LTM) | -20.40% |
ROE (LTM) | -26.53% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CGEM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CGEM | |
---|---|
Trailing PE | NM |
Forward PE | 6.30 |
P/S (TTM) | 26.88 |
P/B | 1.09 |
Price/FCF | NM |
EV/R | 11.55 |
EV/Ebitda | NM |
Cullinan Oncology LLC (CGEM) share price today is $11.8
Yes, Indians can buy shares of Cullinan Oncology LLC (CGEM) on Vested. To buy Cullinan Oncology LLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGEM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cullinan Oncology LLC (CGEM) via the Vested app. You can start investing in Cullinan Oncology LLC (CGEM) with a minimum investment of $1.
You can invest in shares of Cullinan Oncology LLC (CGEM) via Vested in three simple steps:
The 52-week high price of Cullinan Oncology LLC (CGEM) is $30.19. The 52-week low price of Cullinan Oncology LLC (CGEM) is $8.49.
The price-to-earnings (P/E) ratio of Cullinan Oncology LLC (CGEM) is
The price-to-book (P/B) ratio of Cullinan Oncology LLC (CGEM) is 1.09
The dividend yield of Cullinan Oncology LLC (CGEM) is 0.00%
The market capitalization of Cullinan Oncology LLC (CGEM) is $684.17M
The stock symbol (or ticker) of Cullinan Oncology LLC is CGEM